NVDACompany
Nvidia
Compute & simulation
Established exposure
Isaac, Jetson and simulation tools supply robotics developers as well as other AI markets.
The catch
A robotics product offering does not establish a disclosed humanoid revenue share.
A map, with the missing pieces visible
The Exposure Atlas
Twenty companies. Six funds. Three possible futures. Compare what each business does, where the evidence stops, and what could go wrong.
Business descriptions reviewed October 4, 2026. Classifications describe evidence of commercial exposure, not investment quality or revenue percentages. Longevity includes adjacent health and research businesses; no lifespan-extension claim is implied.
26 entries
MSFTCompany
Microsoft
Cloud & applications
Established exposure
Azure supplies an enterprise platform for AI applications and agents.
The catch
AI adoption, infrastructure costs and resulting margins can move in different directions.
Primary evidence ↗2026-10-04
GOOGLCompany
Alphabet
Cloud & models
Established exposure
Google Cloud provides AI models and tools for enterprise development.
The catch
Buying Alphabet also brings exposure to its broader businesses and competitive risks.
Primary evidence ↗2026-10-04
AMZNCompany
Amazon
Cloud infrastructure
Established exposure
AWS supplies cloud AI infrastructure and services.
The catch
Group economics include businesses outside AI; spending is not equivalent to incremental profit.
Primary evidence ↗2026-10-04
AVGOCompany
Broadcom
Semiconductors & networking
Established exposure
Broadcom supplies semiconductor and infrastructure software products.
The catch
Customer concentration and product mix matter; this is not a pure robotics holding.
Primary evidence ↗2026-10-04
TSMCompany
TSMC ADR
Chip manufacturing
Established exposure
TSMC manufactures semiconductors for customers through its foundry business.
The catch
Geopolitics, capital intensity and customer demand affect the whole business.
Primary evidence ↗2026-10-04
VRTCompany
Vertiv
Power & cooling
Established exposure
Vertiv provides power and thermal infrastructure for data centers.
The catch
Orders, delivery, competition and valuation can offset attractive industry demand.
Primary evidence ↗2026-10-04
ETNCompany
Eaton
Electrical infrastructure
Established exposure
Eaton supplies power-management products across multiple end markets.
The catch
Data-center demand is one part of a diversified industrial company.
Primary evidence ↗2026-10-04
TSLACompany
Tesla
Humanoid development
Speculative exposure
Tesla describes Optimus as a general-purpose autonomous humanoid development effort.
The catch
The project page is not evidence of a mature standalone humanoid earnings stream.
TERCompany
Teradyne
Cobots & mobile robots
Established exposure
Its Robotics segment includes collaborative arms and autonomous mobile robots; testing remains a separate major business.
The catch
Industrial robotics exposure is not the same as humanoid exposure.
CGNXCompany
Cognex
Machine vision & perception
Emerging exposure
An existing machine-vision business announced an agreement to acquire RealSense on September 22, 2026.
The catch
An announced acquisition is not a completed transaction; integration and commercial adoption remain to be demonstrated.
ROKCompany
Rockwell Automation
Factory automation
Established exposure
Industrial automation and digital transformation connect equipment to factory operations.
The catch
Broad factory investment can be cyclical; humanoids are a narrower investment thesis.
SYMCompany
Symbotic
Warehouse automation
Established exposure
Symbotic develops automation systems for supply-chain operations.
The catch
Customer concentration, installation execution and economics need separate analysis.
ISRGCompany
Intuitive Surgical
Surgical robotics
Established exposure
Intuitive supplies robotic-assisted surgical systems, including da Vinci.
The catch
Surgical robotics is a different market from general-purpose humanoids.
LLYCompany
Eli Lilly
Medicines & metabolic health
Established exposure
A medicines business provides an adjacent route to researching healthspan.
The catch
Treating disease is not proof that a product extends human lifespan; valuation and clinical evidence matter.
Primary evidence ↗2026-10-04
NVOCompany
Novo Nordisk ADR
Chronic-disease treatment
Established exposure
Novo Nordisk develops medicines for serious chronic diseases.
The catch
Metabolic-health exposure is different from a direct investment in aging reversal.
Primary evidence ↗2026-10-04
RXRXCompany
Recursion
AI drug discovery
Emerging exposure
Recursion uses an AI-enabled platform and drug-development pipeline.
The catch
Discovery progress does not eliminate clinical, financing or commercialization risk.
Primary evidence ↗2026-10-04
TMOCompany
Thermo Fisher Scientific
Research tools & services
Established exposure
Laboratory products and services support research and development.
The catch
Broad life-science spending is an indirect exposure to longevity breakthroughs.
Primary evidence ↗2026-10-04
DHRCompany
Danaher
Life-science tools
Established exposure
Life-science and diagnostic businesses support biological research and healthcare.
The catch
End-market spending and execution can dominate a distant longevity thesis.
Primary evidence ↗2026-10-04
ILMNCompany
Illumina
Genomics tools
Established exposure
Sequencing tools support genomics research and applications.
The catch
Genomics adoption is not itself evidence of successful anti-aging treatments.
Primary evidence ↗2026-10-04
BOTZETF
Global X Robotics & Artificial Intelligence ETF
Diversified fund
Established exposure
Global X describes exposure to industrial and non-industrial robotics, automation and autonomous vehicles.
The catch
A broad robotics label does not promise pure humanoid exposure; inspect dated holdings.
ROBOETF
ROBO Global Robotics & Automation Index ETF
Diversified fund
Established exposure
The fund covers businesses enabling and applying robotics, automation and AI.
The catch
Broad exposure can dilute the specific technology thesis an investor has in mind.
AIQETF
Global X Artificial Intelligence & Technology ETF
Diversified fund
Established exposure
The fund targets companies involved in AI development/utilization and related hardware.
The catch
Check overlap with existing broad-market and technology holdings.
Primary evidence ↗2026-10-04
SMHETF
VanEck Semiconductor ETF
Diversified fund
Established exposure
The fund provides exposure to semiconductor production and equipment.
The catch
Semiconductor concentration is not diversified exposure to the entire AI economy.
Primary evidence ↗2026-10-04
AGNGETF
Global X Aging Population ETF
Diversified fund
Established exposure
The fund focuses on businesses positioned to serve an aging population.
The catch
Aging-population demand and technologies that extend healthy lifespan are different theses.
Primary evidence ↗2026-10-04
XBIETF
State Street SPDR S&P Biotech ETF
Diversified fund
Established exposure
The fund provides broad biotechnology-industry exposure.
The catch
Biotech funds include many businesses unrelated to longevity and carry clinical-development risk.
Primary evidence ↗2026-10-04